Intratumoral Vaccination and Diversified Subcutaneous/Intratumoral Vaccination with Recombinant Poxviruses Encoding a Tumor Antigen and Multiple Costimulatory Molecules

Clinical Cancer Research

Volumn 10, Issue 3, 2004, Pages 1090-1099

  Kudo Saito, Chie ^a   Schlom, Jeffrey ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; TRANSGENE; VIRUS RECOMBINANT;

ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; POXVIRIDAE; TIME FACTORS;

EID: 1042278718     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0145     Document Type: Article

References (43)

1. Hadden, J. W. The immunology and immunotherapy of breast cancer: an update. Int. J. Immunopharmacol., 21: 79-101, 1999.
2. Marshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E., Pedicano, J. E., Gehan, E., Peck, R. A., Arlen, P., Tsang, K. Y., and Schlom, J. Phase 1 study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol., 18: 3964-3973, 2000.
3. Eder, J. P., Kantoff, P. W., Roper, K., Xu, G. X., Bubley, G. J., Boyden, J., Gritz, L., Mazzara, G., Oh, W. K., Arlen, P., Tsang, K. Y., Panicali, D., Schlom, J., and Kufe, D. W. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res., 6: 1632-1638, 2000.
4. Elzey, B. D., Siemens, D. R., Ratliff, T. L., and Lubaroff, D. M. Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int. J. Cancer, 94: 842-849, 2001.
5. Antonia, S. J., Seigne, J., Diaz, J., Muro-Cacho, C., Extermann, M., Farmelo, M. J., Friberg, M., Alsarraj, M., Mahany, J. J., Pow-Sang, J., Cantor, A., and Janssen, W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol., 167: 1995-2000, 2002.
6. Chang, A. E., Li, Q., Jiang, G., Sayre, D. M., Braun, T. M., and Redman, B. G. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J. Clin. Oncol., 21: 884-890, 2003.
7. Eaton, J. D., Perry, M. J., Nicholson, S., Guckian, M., Russell, N., Whelan, M., and Kirby, R. S. Allogeneic whole-cell vaccine: a Phase I/II study in men with hormone-refractory prostate cancer. BJU Int., 89: 19-26, 2002.
8. Simons, J. W., and Mikhak, B. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology. Semin. Oncol., 25: 661-676, 1998.
9. Nemunaitis, J., Bohart, C., Fong, T., Meyer, W., Edelman, G., Paulson, R. S., Orr, D., Jain, V., O'Brien, J., Kuhn, J., Kowal, K. J., Burkeholder, S., Bruce, J., Ognoskie, N., Wynne, D., Martineau, D., and Ando, D. Phase I trial of retroviral vector-mediated interferon (IFN)-γ gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther., 5: 292-300, 1998.
10. Simons, J. W., Mikhak, B., Chang, J. F., DeMarzo, A. M., Carducci, M. A., Lim, M., Weber, C. E., Baccala, A. A., Goemann, M. A., Clift, S. M., Ando, D. G., Levitsky, H. I., Cohen, L. K., Sanda, M. G., Mulligan, R. C., Partin, A. W., Carter, H. B., Piantadosi, S., Marshall, F. F., and Nelson, W. G. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res., 59: 5160-5168, 1999.
11. Wada, Y., Gotoh, A., Shirakawa, T., Hamada, K., and Kamidono, S. Gene therapy for bladder cancer using adenoviral vector. Mol. Urol., 5: 47-52, 2001.
12. Wadler, S., Makower, D., Yu, B., Tan, J. Y., Rozenblit, A., Kaufman, H., Edelman, M., Lane, M. E., and Zwiebel, J. Clinical applications of p53-directed gene therapy. Tumori (Suppl.), 1: S21, 2002.
13. Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., and Kirn, D. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a Phase I trial. Gene Ther., 8: 308-315, 2001.
14. Sakita, M., Takenaka, A., Yamane, T., Kasuga, M., Fujita, Y., and Majima, S. Eradication of microscopic metastases with intratumoral injection of bacillus Calmette-Guerin. Jpn. J. Surg., 14: 413-419, 1984.
15. Kudo, C., Saito, M., and Yoshida, T. The inhibitory effect of preoperative immunochemotherapy on the lymph node metastasis of murine MM48 tumor. Immunopharmacology, 30: 139-146, 1995.
16. Kudo, C., Saito, M., and Yoshida, T. Curative treatments of murine Colon26 solid tumors by immunochemotherapy with G-CSF and OK-432. Immunopharmacology, 29: 235-243, 1995.
17. Duda, R. B., Yang, H., Dooley, D. D., and Abu-Jawdeh, G. Recombinant BCG therapy suppresses melanoma tumor growth. Ann. Surg. Oncol., 2: 542-549, 1995.
18. Calsini, P., Scapicchi, G., Gazzarini, O., Melone, F., Aulisi, A., Pellegrini, G., Fabris, N., and Provinciali, M. Immunotherapy of bladder cancer with intralesional injection with BCG. J. Exp. Pathol., 3: 579-586, 1987.
19. Tanaka, N., Gouchi, A., Ohara, T., Mannami, T., Konaga, E., Fuchimoto, S., Okamura, S., Sato, K., and Orita, K. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer. A randomized trial. Cooperative Study Group of Preoperative Intratumoral Immunotherapy for Cancer. Cancer (Phila), 74: 3097-3103, 1994.
20. Ju, D. W., Cao, X., and Acres, B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma model. Cancer Gene Ther., 4: 139-144, 1997.
21. Todryk, S., McLean, C., Ali, S., Entwistle, C., Boursnell, M., Rees, R., and Vile, R. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer. Hum. Gene Ther., 10: 2757-2768, 1999.
22. Toda, M., Martuza, R. L., and Rabkin, S. D. Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol. Ther., 2: 324-329, 2000.
23. Egilmez, N. K., Jong, Y. S., Sabel, M. S., Jacob, J. S., Mathiowitz, E., and Bankert, R. B. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res., 60: 3832-3837, 2000.
24. Kim, S. H., Carew, J. F., Kooby, D. A., Shields, J., Entwisle, C., Patel, S., Shah, J. P., and Fong, Y. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer. Cancer Gene Ther., 7: 1279-1285, 2000.
25. Qin, H., Valentino, J., Manna, S., Tripathi, P. K., Bhattacharya-Chatterjee, M., Foon, K. A., O'Malley, B. W., Jr., and Chatterjee, S. K. Gene therapy for head and neck cancer using vaccinia virus expressing IL-2 in a murine model, with evidence of immune suppression. Mol. Ther., 4: 551-558, 2001.
26. Colmenero, P., Chen, M., Castanos-Velez, E., Liljestrom, P., and Jondal, M. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int. J. Cancer, 98: 554-560, 2002.
27. Tartaglia, J., Bonnet, M. C., Berinstein, N., Barber, B., Klein, M., and Moingeon, P. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine, 19: 2571-2575, 2001.
28. Mastrangelo, M. J., Maguire, H. C., Jr., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., and Lattime, E. C. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther., 6: 409-422, 1999.
29. Kaufman, H. L., Conkright, W., Divito, J., Jr., Horig, H., Kaleya, R., Lee, D., Mani, S., Panicali, D., Rajdev, L., Ravikumar, T. S., Wise-Campbell, S., and Surhland, M. J. A Phase I trial of intralesional RV-B7.1 vaccine in the treatment of malignant melanoma. Hum. Gene Ther., 11: 1065-1082, 2000.
30. Xiang, J., Chen, Y., and Moyana, T. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer. Cancer Gene Ther., 7: 1023-1033, 2000.
31. Kaufman, H. L., DeRaffele, G., Divito, J., Horig, H., Lee, D., Panicali, D., and Voulo, M. A Phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma. Hum. Gene Ther., 12: 1459-1480, 2001.
32. Peter, I., Nawrath, M., Kamarashev, J., Odermatt, B., Mezzacasa, A., and Hemmi, S. Immunotherapy for murine K1735 melanoma: combinatorial use of recombinant adenovirus expressing CD40L and other immunomodulators. Cancer Gene Ther., 9: 597-605, 2002.
33. Hodge, J. W., Sabzevari, H., Yafal, A. G., Gritz, L., Lorenz, M. G., and Schlom, J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res., 59: 5800-5807, 1999.
34. Grosenbach, D. W., Barrientos, J. C., Schlom, J., and Hodge, J. W. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res., 61: 4497-4505, 2001.
35. Greiner, J. W., Zeytin, H., Anver, M. R., and Schlom, J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res., 62: 6944-6951, 2002.
36. Aarts, W. M., Schlom, J., and Hodge, J. W. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res., 62: 5770-5777, 2002.
37. Eades-Perner, A. M., van der Putten, H., Hirth, A., Thompson, J., Neumaier, M., von Kleist, S., and Zimmermann, W. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res., 54: 4169-4176, 1994.
38. Kass, E., Schlom, J., Thompson, J., Guadagni, F., Graziano, P., and Greiner, J. W. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res., 59: 676-683, 1999.
39. Robbins, P. F., Kantor, J. A., Salgaller, M., Hand, P. H., Femsten, P. D., and Schlom, J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res., 51: 3657-3662, 1991.
40. Morse, M. A. Technology evaluation: CEA-TRICOM, Therion Biologics Corp. Curr. Opin. Mol. Ther., 3: 407-412, 2001.
41. Kass, E., Panicali, D. L., Mazzara, G., Schlom, J., and Greiner, J. W. Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res., 61: 206-214, 2001.
42. Markiewicz, M. A., Fallarino, F., Ashikari, A., and Gajewski, T. F. Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A. Int. Immunol., 13: 625-632, 2001.
43. Pilon, S. A., Kelly, C., and Wei, W. Z. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J. Immunol., 170: 1202-1208, 2003.